AbbVie Inc.
$514.13B- Market cap
- $454.36B
- Debt
- +$65.00B
- Cash
- −$5.23B
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $454.36B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: ABBV stock price vs F: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at F's multiple
Needs F P/E.
Implied fair value · at ABBV's multiple
Needs Annual EPS is negative.
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
Ford Motor Co · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
General Motors Co
ABBV vs GM
Tesla, Inc.
ABBV vs TSLA
Stellantis N.V.
ABBV vs STLA
TOYOTA MOTOR CORP/
ABBV vs TM
HONDA MOTOR CO LTD
ABBV vs HMC
Lucid Group, Inc.
ABBV vs LCID
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV can sustain its much stronger margin structure and growth profile, then avoid using F as a valuation anchor because the comparison heavily penalizes ABBV despite superior fundamentals and instead focus on ABBV's own historical and DCF ranges.
ABBV trades at a severe premium to F implied price of $9.82, with the comparison suggesting -96.2% downside from the current price of $256.10. The gap is driven by ABBV's much richer sales multiple and profitability profile versus F, but the valuation output still points to a wide disconnect on a P/S basis.
Supporting Metrics